ACTRN12622000410752招募中1 期
MDS05: Advancing therapies in Myelodysplasia: . A multi-domain platform trial for patients with myelodysplasia investigating new treatments - The Master Protocol
Australasian Leukaemia and Lymphoma Group (ALLG)0 个研究点目标入组 1,000 人开始时间: 2022年3月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Provision of written informed consent
- •2.Provision of written informed consent to the ALLG NBCR
- •3.Age 18+ (Age 16-17 permitted if consent for minor PICF approved by the authorising HREC)
- •4. A diagnosis of MDS or AML with less than 30% blasts
排除标准
- •1.History of other malignancy requiring active systemic treatment, or which is likely to result in an expected survival time of less than 12 months.
- •2.Viral infection with known HIV or viral hepatitis type B or C not adequately controlled by antiviral medication
- •3.Prior bone marrow or stem cell transplantation for a diagnosis of Myelodysplasia or acute myeloid leukaemia. If stem cell transplantation has been undertaken for other reasons- refer to individual domain and discuss with study team.
研究者
相似试验
Unknown
不适用
An European Platform for Translational Research in Myelodysplastic SyndromesMyelodysplastic SyndromesNCT04174547Istituto Clinico Humanitas8,670
已完成
不适用
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health CareMDS (Myelodysplastic Syndrome)NCT04212390Fondazione Italiana Sindromi Mielodisplastiche-ETS1,000
进行中（未招募）
不适用
Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes.Myelodysplastic SyndromesNCT04399018University Hospital, Grenoble103
已完成
2 期
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS PatientsMDSCMMLNCT04806906University of Florence11
进行中（未招募）
不适用
enalidomide for Myelodysplastic Syndromes: Efficacy, Safety, Cardiac Changes, and Quality of Life (QoL-ESC RevMDS) - QoL-ESC RevMDSow or Intermediate-1 IPSS risk MDS with del(5q)as a single or combined cytogenetic abnormality and with anemiaMedDRA version: 9.1Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersEUCTR2008-000547-34-ITASSOCIAZIONE QOL-ONE